SLC5A2 and heart failure: The study demonstrated that prescription rates for both SGLT-2 inhibitors and GLP-1 agonists varied widely, with general cardiologists and heart failure specialists showing higher rates of prescribing these drugs compared to other subspecialties, such as interventional cardiology and electrophysiology.